Amylyx Settles Class Action for $6.5M, Removing Legal Overhang

What happened

Amylyx has reached a proposed $6.5 million settlement in the securities class action covering the period November 2022 to November 2023, with most costs covered by insurance. This removes a modest legal overhang but does not alter the fundamental binary risk around the LUCIDITY Phase 3 readout in Q3 2026. The settlement was already disclosed as an agreement in principle in the Q1 2026 10-Q, so the news is procedural. Amylyx continues to burn cash at ~$37M per quarter with $280M in cash, funding operations into 2028 but with no committed capital. The stock remains a high-risk binary catalyst play around avexitide's pivotal data and subsequent manufacturing/launch execution.

Implication

The class action settlement is a modest positive as it resolves a legal distraction, but it does not change the investment calculus. Amylyx's value is entirely dependent on a clean LUCIDITY readout and credible CMC commitments to support a 2027 launch. The $6.5M payout is small relative to cash and likely insurance-covered. We maintain our WAIT rating with an attractive entry near $12, as the pre-catalyst risk of dilution or messy data still dominates the risk-reward.

Thesis delta

The settlement was already expected and priced in, so no material shift. Our thesis remains that AMLX offers a binary catalyst with observable de-risking events (no pre-readout financing, CMC commitments) needed before the risk-adjusted return improves. The legal resolution does not change the timeline or the critical path; thus, we keep the WAIT rating and $12 entry target.